The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech
Shanghai Henlius Biotech
University of Roma La Sapienza
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Velindre NHS Trust
SpeciCare
Taizhou Hanzhong biomedical co. LTD
National Cancer Institute (NCI)
University Hospital Schleswig-Holstein